Printer Friendly

Promising bone-building drug in the pipeline.

The experimental drug romosozumab may enhance bone density and help prevent fractures, according to findings published online Jan. 1, 2014, in the New England Journal of Medicine. Researchers compared the effects of romosozumab to a placebo and two drugs currently used to treat osteoporosis in a group of more than 400 women between the ages of 55 and 85 over a 12-month period. The study participants had osteopenia, or low bone mass, but not the more advanced condition of osteoporosis. Women treated with romoso-zumab had increased bone densities in their spines of an average of 11.3 percent, while the two drugs currently used to treat osteoporosis, Forteo and Fosamax, produced increases of 7.1 and 4.1 percent. Most drugs currently used to treat osteoporosis stop the progression of bone loss, but they do not rebuild bones. Romosozumab is believed to be unique in its ability to both stimulate bone production and prevention bone breakdown, or resorption.

COPYRIGHT 2014 Belvoir Media Group, LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:FRONTLINE
Publication:Women's Health Advisor
Date:Apr 1, 2014
Previous Article:Fibromyalgia symptoms may respond to vitamin D supplementation.
Next Article:Cardiovascular disease linked with higher risk of cognitive decline.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters